Navigation Links
SAFC Hitech(TM) Successfully Demonstrates Device-Quality GST Precursors For Phase Change Memory Applications
Date:9/3/2008

in place to control the growth and lay down the correct layers in the correct structure. The temperature window with this process remains critical, and highlights both the difficulties associated with this system and the need for advanced precursors to move forward with integration into future phase change memory applications. We are confident that our sources will allow the development of next-generation devices to maintain the speed of performance enhancement required to meet market targets."

About SAFC Hitech: SAFC Hitech provides a unique chemistry service translating application understanding into performance materials worldwide. Through collaborative partnerships and an integrated approach from research and development, process development and scale up to commercial manufacturing, SAFC Hitech invests in innovation and manufacturing enabling current and future technology needs. Further information can be found at http://www.safchitech.com.

About SAFC: SAFC(R) is the custom manufacturing and services group within Sigma-Aldrich that focuses on high-purity inorganics for high technology applications, cell culture products and services for biopharmaceutical manufacturing, biochemical production and the manufacturing of complex, multi-step organic synthesis of APIs and key intermediates. SAFC has manufacturing facilities around the world dedicated to providing manufacturing services for companies requiring a reliable partner to produce their custom manufactured materials. SAFC has four focus areas -- SAFC Pharma(TM), SAFC Supply Solutions(R), SAFC Biosciences(TM), and SAFC Hitech(TM) -- and had annual sales of nearly $600 million in 2007. SAFC is one of the world's 10 largest fine chemical businesses. For more information about SAFC, visit http://www.safcglobal.com.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Tech
'/>"/>

SOURCE Sigma-Aldrich
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. SAFC Hitech(TM) Expands Sheboygan Facility With State-of-the-Art Manufacturing Cleanroom
2. SAFC Hitech(TM) Plans Further Expansion Into Asia
3. SAFC Hitech(TM) Joins Aviza and ST Microelectronics for Solid State Technology ALD Webcast
4. CoreValve Successfully Treats the First Pacific Rim Patients with Its ReValving System for Percutaneous Aortic Valve Replacement : Australia/New Zealand Regulatory-Cleared Evaluation Registry is Expected to Lead to Market Clearance for These Countries
5. Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
6. Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
7. TopoTarget Successfully Buys Back Full Control of Belinostat
8. Bayer HealthCare Affiliate MEDRAD Successfully Completes Tender Offer for Shares of Possis Medical; Announces Subsequent Offering Period
9. SBT Acquisition Inc. Successfully Completes Tender Offer for Shares of Lifecore Biomedical, Inc.
10. Phase I Safety and Tolerability Study With EVT 302 Successfully Completed
11. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Charles Darwin: More than the origin 2Charles Darwin: More than the origin 3More than fish bait: Worms unlock secrets to new epilepsy treatments 2ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema 28MIVI II DME 29 14355 1ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema 28MIVI II DME 29 14355 2ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema 28MIVI II DME 29 14355 3ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema 28MIVI II DME 29 14355 4Fora Care Group Becomes Pioneering Educational Member of the International Society of Vascular Health 5230 1Fora Care Group Becomes Pioneering Educational Member of the International Society of Vascular Health 5230 2Fora Care Group Becomes Pioneering Educational Member of the International Society of Vascular Health 5230 3Fora Care Group Becomes Pioneering Educational Member of the International Society of Vascular Health 5230 4Kimberly Clark Acquires Baylis Medical Companys Pain Management Business 5227 1Kimberly Clark Acquires Baylis Medical Companys Pain Management Business 5227 2Kimberly Clark Acquires Baylis Medical Companys Pain Management Business 5227 3